Trial Profile
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms FOURward
- Sponsors Bristol-Myers Squibb
- 07 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 26 Feb 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov
- 30 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov